Dr. Justin Park is a Board Certified orthopedic spine surgeon with The Maryland Spine Center at Mercy Medical Center in Baltimore, Maryland.
Our minimally invasive surgeons diagnose and treat Gallbladder/Gallstones in Baltimore.
Dermatology at Mercy is comprised of a team of talented and specially trained doctors who cover a broad spectrum of dermatology specialties.
Dwight D. Im, M.D., FACOG, Director of The Gynecologic Oncology Center at Mercy and The National Institute of Robotic Surgery at Mercy in Baltimore, became the first surgeon in the world to successfully perform a minimally-invasive hysterectomy via robotic surgery using the new Single-Site Wristed Needle Driver, developed by Intuitive Surgical, Inc. (ISRG).
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
The purpose of this study is to understand experiences with an NSCLC condition and to evaluate two questionnaires that ask participants about these symptoms.
The purpose of this study is to compare MPDL3280A carboplatin and paclitaxel versus MPDL3280A plus carboplatin, paclitaxel and bevacizumab versus carboplatin, paclitaxel, and bevacizumab without MPDL3280A in chemotherapy‑naïve patients with stage IV non-squamous non-small cell lung cancer (Clinicaltrials.gov ID#: NCT02366143).
This is a placebo controlled trial evaluating Letrozole with or without BYL719 or Buparlisib, for the neoadjuvant treatment of postmenopausal women who are hormone receptor-positive and HER2/Neu negative. (Clinicaltrials.gov ID#: NCT01923168 )
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
The purpose of this study is to compare the efficacy and safety of MPDL3280A versus standard of care in patients with Stage IB−Stage IIIA non-small cell lung cancer following resection and adjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02486718)
This randomized phase III trial is studying how well giving hormone therapy together with or without everolimus works in treating patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. (SWOG S1207, ClinicalTrials.gov ID#: NCT01674140)
The purpose of this study is to compare MPDL3280A plus nab‑paclitaxel versus placebo plus nab-paclitaxel for patients with previously untreated metastatic triple‑negative breast cancer (Clinicaltrials.gov ID#: NCT02425891).
This study is researching the link between insulin resistance and breast cancer prognosis in African American and Caucasian women.
This phase III study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab (also known as Herceptin®) as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. (Roche BO27938 / NSABP B-50-I / GBG 77, ClinicalTrials.gov ID#: NCT01772472)
The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.
This trial compares olaparib versus placebo as adjuvant treatment in patients with BRCA1 or BRCA2 mutations and triple negative breast cancer (ClinicalTrials.gov ID#: NCT02032823)
This is a prospective, observational study that will assess the impact of MammaPrint on treatment decisions (chemotherapy plus endocrine versus endocrine alone) in patients with an intermediate score by Oncotype DX®. MammaPrint is an FDA-cleared test that may be used to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery. (Clinicaltrials.gov ID#: NCT01617954)
The purpose for the study is to learn whether alpelisib, when added to fulvestrant, helps to reduce the growth of breast cancer cells in people with hormone receptor-positive, HER2-negative advanced breast cancer. (Clinicaltrials.gov ID#: NCT02437318)
The purpose of this study is to compare standard chemotherapy plus margetuximab compared to standard chemotherapy plus Herceptin® for women with metastatic or locally-advanced HER2-positive breast cancer that has progressed following two standard treatments for their cancer.
The objective of this phase III clinical trial is to determine the effect of endocrine therapy with or without chemotherapy in patients with node-positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®. (SWOG S1007, Clinicaltrials.gov ID#: NCT01272037)
This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)
The clinical team of The Prevention & Research Center at Mercy Medical Center in Baltimore, Maryland, offers patients and their families cancer genetic counseling and testing as well as a number of distinctive cancer wellness programs to support cancer recovery and help families manage life after cancer treatment.